Canadian Cancer Trials Group’s Post

🩺 Prostate cancer cases to double in 20 years! A newly published report predicts a significant increase in new cases of prostate cancer globally over the next two decades. The study shows that the annual number of new cases will more than double from 1.4 million in 2020 to 2.9 million by 2040. This increase is attributed to demographic shifts as developing countries catch up with the aging populations of richer countries.

Scientists at NIAID and the National Cancer Institute (NCI) have prospectively identified distinguishing features and patterns in the tumors and lymph-node tissue of people with #FollicularLymphoma who relapsed within 24 months of initial treatment compared with those who did not. These findings could help clinicians predict early relapse among people with follicular lymphoma and inform treatment decisions. The scientists conducted the research in part with technology they created—an imaging system called IBEX—that enabled a fine-grained analysis of lymph-node cells in the context of their tissue microenvironment. The findings are published in the journal Cancer Cell. Read more: https://lnkd.in/e_A9h_PW More on IBEX: https://lnkd.in/eerHscxN #NIH

New in JCO Global Oncology! This issue supplement highlights 136 scientific abstracts from the 12th Annual Symposium on Global Cancer Research (ASGCR), featuring cancer research conducted in over 65 countries. Additionally, the ASGCR Steering Committee reflects on the importance of equitable collaborations in global cancer research, in the accompanying editorial. Read more 🔗 https://go.nih.gov/VqEH27q. American Society of Clinical Oncology (ASCO), American Association for Cancer Research, AFRICAN ORGANIZATION FOR RESEARCH AND TRAINING IN CANCER AORTIC INC, American Society of Preventive Oncology, Consortium of Universities for Global Health, TATA MEMORIAL HOSPITAL, & Red de Institutos Nacionales de Cáncer/Sociedad Latino Americana y del Caribe De Oncología Médica (RINC-SLACOM) #CancerResearch #CancerControl #GlobalHealth

🔬 Revolutionary Insights on Colorectal Cancer! 🔬 Colorectal cancer (CRC) continues to pose a significant challenge in oncology due to its latent progression and dismal prognosis. But a beacon of hope emerges in the form of ferroptosis—a novel mode of cell death that promises to reshape current treatment paradigms. In the latest research, scientists delve deep into understanding how ferroptosis operates within CRC. This exploration not only uncovers the regulatory dynamics but also highlights interactions with the immune system that could provide new therapeutic pathways. With the potential for targeted ferroptosis-based treatments, there's hope for more effective interventions. Advances in radiotherapy, immunotherapy, and even herbal approaches are being explored to harness this mechanism in the fight against CRC. Stay tuned as these groundbreaking discoveries pave the way for future strategies in CRC management. 🚀 Read Research 👉🏻 https://lnkd.in/dbZMhjJR #research #pubmed

A systematic review reveals distinct characteristics of early-onset colorectal cancer. It's less likely to involve KRAS, BRAF, and APC mutations but shows higher rates of TP53 and PTEN mutations. Additionally, it's linked to more aggressive histological features like high-grade and signet ring cell histologies. These findings underscore the importance of developing specialized treatment approaches for this younger patient group, potentially leading to better prognostic outcomes. Let’s discuss how these insights can transform care for early-onset CRC patients. #ColorectalCancer #CancerResearch #MedicalInnovation 🧬

Recently we met with John Strickler, MD, Associate Professor of Medicine in the Division of Medical Oncology at Duke University to discuss new treatments for #PancreaticCancer. Dr. Strickler specializes in the treatment of esophageal, gastric, pancreatic, and colorectal cancers, with a focus on clinical trials. Clinical trial patients usually come to him looking for an #AlternativeTherapy once standard treatments have not been effective. He recently published results on a study of pancreatic cancer patients with a specific mutation (#KRAS G12C). The seesion includes a discussion of: -What are the improvements in treatments for pancreatic cancer coming online today? -What are future improvements to keep an eye on? -What are the challenges in finding additional future treatments for pancreatic cancer? What action can you take? This session is roughly an hour, so grab your coffee and enjoy learning from this outstanding expert in the field of Oncology.

Huge congratulations to Dr Pat Bowden and the TRANSFORM trial team for their recently published results in the International Journal of Cancer.    This study highlights the potential for stereotactic radiotherapy to delay hormone therapy and chemotherapy for over five years in some men with metastatic prostate cancer.   What excites me most about these findings is the shift toward more targeted, precise treatments that not only control disease but also preserve quality of life. With no significant high grade toxicities, stereotactic radiation is an example of how we can deliver powerful results with fewer side effects.   Through research, collaboration and further personalised treatments we are helping redefine cancer care.   Learn more: https://lnkd.in/g7MbtNs9   #radiotherapy #prostatecancer #stereotacticradiation #cancercare #cancerresearch Icon Group Icon Cancer Centre - Australia & New Zealand  

🔔 🔔 🔔 Newly Published Article! Title: Ribociclib plus Letrozole Alters the Blood Immune Profile in Older Patients with HR+/HER2- Metastatic Breast Cancer Authors: Yentl Lambrechts, Sigrid Hatse*(from KU Leuven), et al. The study shows that the combination of ribociclib and ET modulates the immune system in older patients, potentially reversing the age-related immunosenescence process by increasing naïve T-cell and B-cell populations and decreasing memory populations. Keywords:#Breast cancer; #Biomarkers; #Immunity; #Translational research; #Geriatric oncology Welcome to read and share! 🌹 🌹 https://lnkd.in/gJEu9QAj PDF for free: https://ojs.gs- https://lnkd.in/gGx-ApuZ

Congrats to Dr. Jaehyuk Choi (@jaehyukchoiMD), professor at Northwestern University #CBCAwardee, and founder of #biostartup Moonlight Bio, which engineers better T-cells to fight cancer. Dr. Choi's new research published in Nature has shown that with a few mutations CAR T-cells can be modified to attack solid tumors, like those found in breast and lung cancer. This is big news. While the FDA has already approved several CAR T-cell therapies for lymphoma and multiple myeloma, creating a method to use CAR T-cells to treat solid cancers has remained elusive. With these new findings, Dr. Choi and co-founder Dr. Roybal are hoping to start clinical trials with these newly modified CAR T-cells within the next three years. Read more here: https://lnkd.in/gewyR6p3 #ChicagoBiotech #FightCancer #ChicagoCancerResearch

Advancing #PrecisionOncology: Standardizing Tumor Mutational Burden for #cancerimmunotherapy ◾ #TMB is emerging as a key #biomarker for predicting #cancerimmunotherapy response across various cancer types. Despite its potential, significant variability exists in how TMB is calculated and reported by different laboratories. ◾ Addressing this, the Association for Molecular Pathology (AMP) , in collaboration with American Society of Clinical Oncology (ASCO), College of American Pathologists (CAP), and Society for Immunotherapy of Cancer (SITC), has formed a multidisciplinary group to create comprehensive recommendations for the #analyticalvalidation and #reporting of TMB. ◾ These recommendations aim to #standardize practices and ensure reliable, comparable results across different #assays, ultimately enhancing the precision and effectiveness of cancer immunotherapy. 🔗https://lnkd.in/dYhVvkk6